Nigeria unveils new HIV prevention injection to reduce infection rates

0
176

Nigeria has taken a major step forward in its public health response with the introduction of a new long-acting injectable known as lenacapavir, designed to strengthen HIV prevention across the country.

This development marks a shift toward more modern and user-friendly prevention tools, aimed at reducing new HIV infections and improving adherence to treatment and prevention strategies.

The rollout of the injectable HIV prevention drug was announced by the Minister of State for Health and Social Welfare, Dr. Iziaq Salako, during a media briefing in Abuja.

He explained that the introduction of lenacapavir reflects Nigeria’s commitment to adopting innovative solutions in the fight against HIV.

The new drug is designed as a pre-exposure prophylaxis (PrEP), offering protection when administered every six months.

HIV

One of the key advantages of this new HIV prevention method is its long-lasting nature.

Unlike daily oral medication, which requires strict adherence, the injectable is administered only twice a year.

This significantly reduces the burden on individuals and helps improve consistency in protection against HIV infection.

Health experts believe this convenience could encourage more people, especially those at higher risk, to adopt preventive care.

Dr. Salako highlighted that the government has already secured about 52,000 doses of the injectable HIV drug to support its introduction.

The first phase of the rollout will focus on selected states, including Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, Benue, and the Federal Capital Territory.

These locations were chosen to ensure effective monitoring and gradual scaling of the program before nationwide expansion.

The introduction of this HIV prevention tool was not done hastily. According to the minister, extensive groundwork was carried out before implementation.

This included regulatory approvals, training of healthcare workers, assessing the readiness of health facilities, and strengthening the supply chain to ensure that the injectable HIV drug reaches those who need it without interruption.

Health authorities believe that the addition of lenacapavir will complement existing HIV prevention strategies, such as oral PrEP and other long-acting interventions.

Rather than replacing current methods, the new option expands the range of choices available, allowing individuals to select what best suits their lifestyle and health needs.

This flexibility is expected to improve uptake of HIV prevention services nationwide.

The Director-General of the National Agency for the Control of AIDS (NACA), Temitope Ilori, also weighed in on the new development.

She noted that while the injectable HIV drug has shown strong safety and effectiveness globally, it is not recommended for pregnant women due to limited data on its use during pregnancy.

She emphasized the importance of medical guidance when considering any HIV prevention method.

Ilori further explained that although the injectable plays a significant role in reducing HIV transmission, it does not provide protection against other sexually transmitted infections.

She urged individuals to continue practicing safe behaviors and to use additional protective measures when necessary.

The National Coordinator of NASCP, Dr. Adebobola Bashorun, added that efforts are ongoing to expand access to the injectable HIV prevention drug beyond the initial states.

The government is exploring additional funding opportunities to increase the availability of doses and ensure wider coverage, especially among vulnerable populations.

He stressed that the introduction of lenacapavir is part of a broader strategy to enhance HIV prevention in Nigeria.

By combining new technologies with existing approaches, the country aims to reduce the spread of HIV and move closer to achieving its long-term goal of ending AIDS as a public health threat by 2030.

Overall, the rollout of this injectable HIV prevention drug represents a significant milestone in Nigeria’s healthcare system.

It reflects a growing commitment to innovation, accessibility, and improved health outcomes.

As the program expands, health officials remain optimistic that this new approach will play a key role in reducing HIV infections and strengthening the country’s overall response to the epidemic.

Ireport247news

About The Author

LEAVE A REPLY